Disparities Still Exist for HCC Incidence, Survival in United States
A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.
Aspirin Use Linked to Decreased Risk of Bile Duct Cancer
Regular use of aspirin may reduce the risk of developing cholangiocarcinoma, according to the results of a new study.
Incidence of Hepatocellular Carcinoma May Decline
Researchers from the National Cancer Institute are predicting that the rate of hepatocellular carcinoma (HCC) in the United States will likely decrease by the year 2030.
Hispanic Origin Influenced Risk for Hepatocellular Carcinoma
US-born Hispanics are more likely to get hepatocellular carcinoma and to die from chronic liver disease compared with their foreign-born counterparts.
RFA, SBRT Both Good Options for Unresectable Hepatocellular Carcinoma
Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.
Panitumumab Failed in KRAS Wild-Type Biliary Tract Cancer
Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.
Blood Clots in Abdomen May Be Sign of Cancer
The presence of an abdominal blood clot may be a sign of cancer and may also be associated with poor survival for patients with pancreatic or liver cancers.
PD-1 Inhibitor Yields Responses in Hepatocellular Carcinoma
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.